PERTH, Australia, 5th September 2017: Phylogica Limited (ASX:PYC) (Phylogica or the Company), developer of a leading intracellular drug delivery platform technology, is pleased to provide an update on its core Functional Penetrating Peptide (FPP) platform delivery technology.
Phylogica’s primary objective is to harness the ability of its FPP platform to deliver drug cargoes inside cells as next generation therapies for a range of diseases. Delivering drug cargoes inside cells provides access to 10 times as many drug targets as those currently accessible. A key activity for this half of CY2017 is expanding the number FPPs that have the ability to deliver drug cargo into cells.
For further information please download PDF attached:
Download this document
